Boston, MA — Basil Systems, an AI-powered intelligence platform transforming how life sciences companies make strategic decisions, has raised $11.5 million in funding to expand its technology and reach. The round was led by Golden Ventures with participation from Hearst Ventures and Argosy Capital.
The funding will support the expansion of Basil’s enterprise SaaS platform, BasilIntel, enabling the company to enhance its data coverage, onboard new enterprise clients, and further deploy AI and machine learning capabilities to automate complex, high-stakes workflows across the pharmaceutical and medtech industries.
Basil Systems tackles a core challenge in life sciences: the reliance on outdated, siloed systems for managing vast volumes of regulatory, clinical, and post-market data. By leveraging artificial intelligence and one of the largest structured datasets in the sector—over 600 million indexed records—the company provides real-time, actionable insights that streamline product development, regulatory submissions, safety monitoring, and market strategy.
“Basil Systems is transforming how life sciences companies access and act on regulatory intelligence,” said Bert Amato, Venture Partner at Golden Ventures and a Basil board director. “What used to take teams weeks or even months can now be achieved in real time, helping to drive smarter decisions and faster approvals.”
The company’s proprietary platform consolidates fragmented data—ranging from regulatory filings and clinical trials to drug labels, adverse events, and recalls—into a searchable, full-text interface. Users can ask detailed questions and receive quick answers powered by natural language processing and machine learning. API integration and enterprise-grade infrastructure allow the platform to support millions of concurrent users.
“Our goal is to redefine how strategic decisions are made in life sciences,” said Anthony Cirurgiao, CEO and founder of Basil Systems. “With the largest structured dataset in the industry, we are enabling companies to go beyond basic analytics and act on real-time insights that directly impact innovation, safety, and commercial success.”
Basil Systems already counts four of the five largest global medical device firms as clients and is in active trials with three of the world’s top pharmaceutical companies. Its platform is used for a range of functions beyond regulatory intelligence, including product development, real-world evidence analysis, supply chain optimization, and risk mitigation.
“Basil has built a centralized intelligence engine for how medical products are developed, approved, and perform in-market,” said Mohamed Shariff, Director of Regulatory Affairs at Johnson & Johnson. “It’s becoming the default infrastructure layer for data-driven strategy in life sciences.”
With this latest funding, Basil Systems aims to expand its presence across the broader life sciences ecosystem, including drug and device manufacturers, suppliers, contract research organizations, and regulatory agencies—positioning itself as a core intelligence provider in an industry increasingly driven by speed, accuracy, and data.
